Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Elizabeth M E VerdegaalSaskia J A M SantegoetsMarij J P WeltersLinda de BruinMarten VisserCaroline E van der MinnePita M de KokNikki M LoofSanne BoekestijnInge RoozenInge M WestraPauline MeijSjoerd H Van der BurgJudith R KroepPublished in: Journal for immunotherapy of cancer (2023)
TIL therapy can be safely combined with platinum-based chemotherapy but not in combination with IFNa. The chemotherapy-mediated reduction in immunosuppression and the increase in platinum-free interval for two patients warrants further exploration of properly-timed TIL infusions during platinum-based chemotherapy, possibly further benefiting from IL-2 support, as a novel treatment option for EOC patients.